Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part one: Bleeding and anticoagulation issues

Heart Lung and Circulation

Volumn 10, Issue 3, 2001, Pages 142-153

  Robinson, Kathryn L ^a   Marasco, Silvana F ^b   Street, Alison M ^b  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Anticoagulation; Blood coagulation; Cardiac surgery; Cardiopulmonary bypass; Haematological agents; Haemostasis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALCOHOL; AMINOCAPROIC ACID; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; DESMOPRESSIN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOLYTIC AGENT; GLYCOPROTEIN IIB; HEMOSTATIC AGENT; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; STEROID; TICLOPIDINE; TIROFIBAN; TRANEXAMIC ACID; WARFARIN;

ADULT; ANESTHESIST; ANTICOAGULATION; BLOOD; CHILD; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; EXTRACORPOREAL CIRCULATION; FEMALE; HEALTH CARE POLICY; HEART SURGERY; HEMATOLOGY; HEMOSTASIS; HISTORY; HUMAN; MEDICAL AUDIT; MEDICAL PRACTICE; MEDICAL SPECIALIST; PATIENT CARE; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SURGEON; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSFUSION;

EID: 0035673358     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-2892.2001.00096.x     Document Type: Review

References (62)

1. Usefulness of patient interview in bleeding disorders
2. Frequency of inherited bleeding disorders in women with menorrhagia
3. Cardiac bypass haemostasis: Putting blood through the mill
4. A randomized and blinded comparison of three bleeding time techniques: The Ivy method, and the Simplate II method in two directions
5. The preoperative bleeding time test lacks clinical benefit. College of American Pathologists' and American Society of Clinical Pathologists' position article
6. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center
7. Are in vitro platelet function tests useful in predicting blood loss following open heart surgery?
8. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft
9. Vitamin K reduces bleeding in left ventricular assist device recipients
10. ABC of clinical haematology The myelodysplastic syndromes
11. The use of aspirin in polycythaemia vera and primary thrombocythaemia
12. Coagulation-factor deficiencies and abnormal bleeding in Noonan's syndrome
13. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease
14. Cardiac surgery and catheterization in patients with haemophilia
15. Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery
16. Antiphospholipid syndrome and cardiac surgery: Management of anticoagulation in two patients
17. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation
18. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia
19. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution
20. Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition
21. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
22. Treatment of heparin-induced thrombocytopenia
23. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation
24. Management of anticoagulation before and after elective surgery
25. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy
26. Low-molecular-weight heparin in extracorporeal circulation [letter]
27. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers
28. Poor reversal of low molecular weight heparin by protamine [letter]
29. Aprotinin used in emergency coronary operation after streptokinase treatment
30. Reversal of streptokinase-induced bleeding with aprotinin for emergency cardiac surgery
31. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
32. Group Recommendations
33. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
34. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
35. Postoperative care
36. Resternotomy for bleeding after cardiac operation: A marker for increased morbidity and mortality
37. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery
38. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation
39. Coagulation tests predict bleeding after cardiopulmonary bypass
40. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery
41. Variability of the activated coagulation time
42. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
43. Synthetic antifibrinolytics and aprotinin for cardiac surgery
44. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome
45. Effect of aprotinin on transfusion requirements during repeat sternotomy for cardiac transplantation surgery
46. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and peri-operative mortality
47. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial
48. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints
49. Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass
50. Aprotinin inhibits fibrinolysis, improves platelet adhesion and reduces blood loss. Results of a double-blind randomized clinical trial
51. Postoperative use of aprotinin in cardiac operations: An alternative to its prophylactic use
52. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens
53. Plasma aprotinin concentrations during cardiac surgery: Full-versus half-dose regimens
54. Prevalence of anaphylactic reactions to aprotinin: Analysis of two hundred forty-eight reexposures to aprotinin in heart operations
55. Safety of repeat aprotinin administration for LVAD recipients undergoing cardiac transplantation
56. Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: Efficiency, safety and cost
57. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: A randomized, blinded clinical trial
58. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding
59. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: A double-blind, randomized, placebo-controlled trial
60. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: A randomised controlled trial
61. Thrombotic and hemorrhagic problems during cardiopulmonary bypass surgery and cardiovascular procedures